Clinical trial · Interventional
Whole-body Diffusion MRI for Staging, Response Prediction and Detecting Tumor Recurrence in Patients With Ovarian Cancer
NCT01657747CI-TRIAL-00018429S53580completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to assess whole body diffusion weighted imaging (WB-DWI) as a non-invasive method for * accurate staging of patient suspected having ovarian cancer * early treatment assessment * detecting tumor recurrence
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Ovarian Carcinoma | Ovarian Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Whole body diffusion-weighted MRI | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- NO_INTERVENTION
- label
- Not applicable (imaging study)
- interventionNames
- Other: Whole body diffusion-weighted MRI
Primary outcomes (3)
- measure
- Validation of interpretation criteria of WB-DWI for staging and thresholding for treatment assessment in pilot study
- timeFrame
- Nov 2011 - Sep 2012 (up to 1 year)
- description
- Validation of interpretation criteria of WB-DWI for staging and thresholding for treatment assessment in pilot study
- measure
- WB-DWI for tumor characterization and staging at primary diagnosis
- timeFrame
- Nov 2011 - Nov 2015 (expected) (up to 4 years)
- description
- The aim of this part of the study is to prospectively evaluate WB-DWI for tumor characterization and staging at primary diagnosis in comparison to CT and combined CT/diagnostic laparoscopy with the aim to assess patient operability.
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: * STAGING: patients with suspected ovarian carcinoma * EARLY TREATMENT ASSESSMENT: patients with FIGO stage IIIc or IV ovarian carcinoma who will undergo neoadjuvant chemotherapy * IDENTIFYING TUMOR RECURRENCE: patients with a medical history of ovarian carcinoma with suspicion of recurrent ovarian cancer after a disease-free-interval of at least 6 months Exclusion Criteria: * patients with known contra-indications for MRI (cardiac pacemakers, cochlear implants, claustrophobic patients)will be excluded from this study. * patients with contra-indications to gadolinium-based contrast agents (including patients with a known restricted renal function; GFR \< 30 mL/min)and/or Buscopan
References
Publications (0)
Data not yet available
No reference posted for this study.